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S. BRET SNYDER, Albuquerque Biological Park, Rio Grande Zoo, 903 10th Street S.W., Albuquerque, NM 87102, USA
MICHAEL J. RICHARD, Albuquerque Biological Park, Rio Grande Zoo, 903 10th Street S.W., Albuquerque, NM 87102, USA
CAROL U. METEYER, National Wildlife Health Center, 6006 Schroeder Road, Madison, WI 537", USA

Abstract:

A whooping crane (Grns americana) confirmed as suffering from Mycobacterium avium infection was treated for 1 year
with daily doses of rifampin (45 mg/kg) and ethambutol (30 mg/kg) and 2 doses of M. vaccae antigen. Remission of disease occurred
during therapy; however, recrudescence to active infection was suspected by 10 months after the antitubercular drugs were
discontinued when the crane exhibited weight loss and had thickening of bowel wall as seen on radiographs. A second therapeutic
regimen using azithromycin was then initiated (40 mg/kg fed daily) and was accompanied by a second remission within 6 weeks. After
16 weeks of azlthromycin therapy, ethambutol (30 mg/kg daily) was added to the azithromycin to reduce the probability of emergent
drug resistance. Three weeks later the crane developed severe hepatic dysfunction as suggested by blood chemistry values. This
contributed to the crane's collapse and eventual death. All tissues cultured were negative for M. avium infection. A severe hepatopathy
and chronic fibrosing cardiomyopathy may have resulted from the drug combinations. This case suggests azithromycin as a promising
therapeutic agent in treatment of avian tuberculosis and warrants further investigation.
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Treatment of avian tuberculosis is seldom attempted
because of the long time interval for assessing outcome of
treatment and the potential for suppression of disease rather
than cure. This may result in recrudescence, further·
transmission of infection, and increased zoonotic exposure
(Bush et a1. 1978, Farer 1978, Beehler 1990). However,
endangered species or otherwise valuable birds may justify
special consideration. Recent reports suggest treatment can be
successful in some cases of avian mycobacteriosis (Rosskopf
and Woerpel 1991, VanDerHeyden 1994) although these
diagnoses were not confirmed as M. avium infection by
bacterial isolation. Drugs used in treatment of psittacine
species were various combinations of isoniazid, rifampin,
ethambutol, streptomycin, clofazimine, and cyclocerine. This
report follows the course of treatment and outcome over 29
months of a whooping crane infected in the wild with M.

avium.
We thank 1. P. Thilsted, New Mexico Veterinary
Diagnostic Services (NMVDS), New Mexico Department of
Agriculture, for biopsy histopathology and R. B. Ferguson,
Tuberculosis and Mycology Section, Scientific Laboratory
Division, New Mexico Department of Health, for isolation
and identification of M. avium complex. D. G. Teubert,
Senior Research Specialist, Department of Pathobiological
Sciences, School of Veterinary Medicine, University of
Wisconsin- Madison, verified the isolate as M. avium by
DNA probe. R. L. Cromie, The Wildfowl and Wetlands
Trust, United Kingdom, provided M. vaccae antigen, and S.
B. Kadin and D. 1. Williams, Pfizer Laboratories, Inc.,
Groton, Comlecticut, donated azithromycin. Helpful comments were given by 1. C. Lewis, U.S, Fish and Wildlife
Service (USFWS), and by other reviewers of the manuscript.
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CASE REPORT
A debilitated 5-year-old male whooping crane from the
experimental Rocky Mountain flock (Drewien and Bizeau
1978) was captured at the Monte Vista National Wildlife
Refuge, Colorado, and transported to the Rio Grande Zoo,
Albuquerque, New Mexico, on 5 November 1992 by
University of Idaho biologists. Details of the initial case
presentation, diagnostic workup, and patient management
have been reported (Snyder and Richard 1994). At initial
examination the bird was thin (weight 5.78 kg) and had a
large, easily palpable, mid-coelomic mass and a chronic
cloacal prolapse. A firm 2-cm tissue mass was palpable
within the prolapsed tissue.
Initial diagnostic tests included blood samples for
hematology and serum biochemistry, feces for ova and
parasites, whole body radiographs, and biopsy and culture of
the tissue mass in the wall of the prolapsed cloaca. Radiographs and biopsy were done under isoflurane anesthesia.
The prolapse was reduced and held in place with a pursestring suture.
Radiographs confirmed a large, mid-coelomic soft tissue
density and splenomegaly. The initial white blood cell count
(WBe) was estimated to be elevated (8-10 WBC/oil immersion field). Dissection of the cloacal mass revealed pockets
of brownish, inspissated exudate within a firm fibrous-like
stroma. Histologically, there were numerous coalescing
granulomas with necrotic centers surrounded by zones of
macrophages. An acid fast strain showed rod-shaped, acidfast bacteria in the centers of many of the granulomas. The
preliminary diagnosis was avian tuberculosis, and a decision
was made to attempt treatment based on reports of success in
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some psittacine species (Rosskopf and Woerpel 1991,
VanDerHeyden 1994). Mycobacteriosis or other granulomatous diseases were differential diagnoses. M. avium complex
was confirmed in 3 weeks by isolation from the biopsy tissue
(organism on file, NMVDS). The isolate was later verified
as M. avium by use of a specific DNA probe for this organism.
First Treatment Regimen

Antitubercular treatment was initiated on 12 November
1992 when the bird began to self feed, and was continued for
1 year. Rifampin (Rifadin, Marion Merrell Dow, Inc.) and
ethambutol (Myambutol, Ledede) were started at 30 mg/kg
daily. The measured portion of powder and tablet were
loaded into gelatin capsules and placed into the body cavity
of a mouse or herring, which the bird ate. The dosage of
rifampin was increased to 45 mg/kg daily (on 10 December
1992) for the remainder of the treatment year. Isoniazid
(Isoniazid, USP, Rugby Laboratories) was unsuccessfully·
added as a third antitubercular drug at a dose of 30 mg/kg
daily on 2 occasions early in treatment. On both attempts the
bird became anorectic within 3 days but resumed eating when
isoniazid was discontinued.
The purse-string suture at the cloaca was removed in
mid-January when pericloacal swelling had regressed
sufficiently. M. vaccae antigen (Cromie 1991) was started at
that time. Two O.05-mt doses of the vaccine were given
intradermally 8 weeks apart in the thick skin on top of the
head.
Monitoring of the patient throughout treatment was by
physical examinations, radiography, hematology, serum
biochemistry, and feces collection for demonstration of acidfast bacilli by staining and by mycobacterial culturing. These
data were collected at various intervals from monthly to
quarterly throughout treatment. The mid-coelomic mass and
spleen were markedly reduced in size by 9 March 1993, 4
months after treatment with antitubercular drugs was begun.
At this time the cloacal mass was palpable at less than I cm.
Nine months after treatment was started (6 August 1993), all
tests were within normal parameters, including radiographs.
The cloacal mass was no longer palpable. The WBC (by
eosinophil Unopette method) had decreased from 32,787/,u1
on 16 December 1992 to 6,2061,u1 on 6 August 1993.
The bird continued to appear normal on 10 June 1994, 6
months after administration of antitubercular drugs was
discontinued, although it had experienced a weight loss of
0.22 kg from 25 February 1994. This weight loss was
possibly an early manifestation of recrudescence. Sequential
blood values during treatment and observation have been
reported (Snyder and Richard 1994).
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Second Treatment Regimen

By 15 September 1994 there was additional weight loss
of 0.28 kg and an increase in the WBC from 10,304/,u1 in
June 1994 to 20,2801,u1. Radiographs taken 23 September
1994 showed prominent loops of intestine in the pelvic
region which were interpreted as uniform thickened bowel
wall. No other abnormal findings were evident; the bird's
appetite was normal and fecal cultures were negative for
mycobacteria.
Although M. avium was not again isolated from the bird
by fecal culture, we considered recrudescence of infection as
the cause of the recurrent wasting illness and bowel wall
thickening. Treatment with azithromycin (Pfizer Laboratories, Inc.) was initiated 26 October 1994 at 20 mg/kg given
in food daily. After 1 week the dose was increased to 40
mg/kg and was continued 16 weeks unti115 February 1995
with no ill effect. We decided to initially give azithromycin
alone to test its potential usefulness in treatment. The bird
made a dramatic improvement~ weight gain was 0.57 kg over
the first 6 weeks on azithromycin (26 October to 8 December
1994) and the WBC dropped to < 10,000/,ul. The bird again
appeared in full remission.
Third Treatment Regimen

The drug manufacturer recommended using azithromycin
in combination with other antibiotics to reduce the probability of emergence of drug resistant M. avium. Thus, after 16
weeks of azithromycin therapy, a second antibiotic, ethambutol (30 mg/kg daily), was added (starting 15 February
1995). After 3 weeks of treatment with this combination (8
March 1995), the bird was found collapsed and unable to
stand; both antibiotics were discontinued. Body weight had
dropped 1.5 kg (to 4.69 kg), WBC was 10,442/,u1, and
serum aspartate aminotransferase (AST) was> 760 mg/dl.
The serum AST had been 310 mg/dl in June 1994 and 321
mg/dl in September 1994. Tube feeding and intensive
supportive care were initiated and continued for 3 weeks as
the bird' s condition worsened until euthanasia was performed
on 4 April 1995. The carcass was submitted to National
Wildlife Health Center, Madison, Wisconsin, for complete
necropsy.
Feces were collected for acid-fast bacilli (AFB) stain and
mycobacterial culture on 17 occasions between 12 November
1992 and 10 March 1995 (29 months). AFB stains were
negative on all samples. Cultures were negative for mycobacteria in 9 of the samples; M. Jortuitum was isolated from 1
sample (28 January 1994), M. terrae was isolated from 2
samples (23 August 1994 and 23 November 1994), and 5
samples were overgrown by contaminant bacteria.
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Necropsy Findings

A complete necropsy was performed including gross and
histopathology, virology, parasitology, bacteriology, and TB
culture. Gross necropsy revealed significant lesions involving
the heart and liver. There was serosanguinous fluid within the
pericardial sac, a mildly cloudy pericardium, and a pale area
on the left ventricular wall. The liver was large with rounded
borders and was orange/red and mottled. Bile was red-tinged
and watery. There was no evidence of the coelomic or
cloacal masses found at initial presentation and no tuberculartype lesions were seen in the gastrointestinal tract, liver, or
spleen. Histologic lesions were a severe chronic active
fibrosing cardiomyopathy and a severe hepatopathy that was
suggestive of a toxic reaction. Acid-fast stains failed to reveal
evidence of acid-fast bacteria, and no mycobacteria were
recovered from cultures of spleen, liver, and ceca.
DISCUSSION

Avian tuberculosis, confirmed by isolation of M. avium
from granulomatous tissue, was resolved in this whooping
crane before its death from an apparent adverse drug reaction
(azithromycin + ethambutol). The first drug regimen
(rifampin + ethambutol + M. vacca e) induced remission of
disease, but 10 months after the antitubercular drugs were
discontinued, the recurrence of wasting illness suggested
recrudescence of infection. Treatment with azithromycin
brought about a rapid and pronounced second remission. It is
unknown if the final combination (azithromycin + ethambutol) contributed to the control of infection or if the apparent
cure had already been effected. Although the results of
necropsy suggest that mycobacterial infection was resolved,
a sufficient time interval to assess the long-term outcome was
not possible.
Azithromycin, a macrolide antibiotic, has shown in vitro
and in vivo activity against M. avium complex infection in
persons with AIDS (Young et a1. 1991, Cynamon and
Klemens 1994). The results of this clinical trial suggest
further investigation of azithromycin as a promising therapeutic agent for M. avium infection in birds.
The etiology of the hepatopathy and cardiomyopathy found
at necropsy cannot be proven, but the toxic nature of the
changes and their temporal relationship to drug therapy
(azithromycin + ethambutol) suggest an adverse reaction to
the drugs. A recent report describes fulminant hepatic failure
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in humans undergoing antitubercular therapy with rifampin
and/or isoniazid (Mitchell et al. 1995). A similar event likely
occurred in this bird when given azithromycin and ethambutol.
Fecal AFB strains and cultures were not reliable for
either diagnosis or surveillance of infection in this whooping
crane. These tests were negative before and during treatment
as well as during recrudescence. Accurate diagnosis required
biopsy of affected tissue.
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